Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (May 2019)
28 slides from Aurobindo Pharma's investor presentation, May 2019
Slide 1: Leading Vertically Integrated Generic Player
LEADING VERTICALLY INTEGRATED GENERIC PLAYER Investor Presentation - May 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any
Slide 3: Aurobindo Pharma – Overview
Aurobindo Pharma – Overview 10th Largest generic 2nd Largest listed 2nd Largest generic Amongst Top 10 Gx 32 years company by sales Indian Pharmaceutical Company by Rx companies in 4 out in existence globally# company by revenues* dispensed in the US** of Top 5 Europe Countries@ $ 2.8 Bn 27 Manufact
Slide 4: The Journey So Far…
The Journey So Far… 2014 - 16 Acquired Western European commercial operations from Actavis Acquired Natrol Established OTC presence Entered into Biosimilars and Vaccines Filed first peptide DMF 2006-08 2017-19 Acquired UK based Milpharm Acquired Generis in Portugal and Apotex Inc’s A
Slide 5: Emerged into a leading global generic player
Emerged into a leading global generic player Revenue (INR Cr) EBITDA (INR Cr) & Margin Net Profit (INR Cr) Geographical Revenue Mix 20% 2,365 19,564 International Domestic 3,952 10 39 90 3,077 61 9% 100 266 FY09 FY19 FY09 FY19 FY09 FY19 FY09 FY18 Business Mix Employee Base ANDAs – Filing Status DMFs
Slide 6: Core Strengths
Core Strengths • Among Top 3 in >63% of commercial portfolio in US(1) in terms of prescriptions • Large US portfolio(2) - 541 ANDAs filed; 377 with final approval, 26 Tentative approval(3), and 138 under review Scale & Diversity • Extensive product portfolio & pipeline across the globe • Experienced
Slide 7: US Business Highlights
US Business Highlights Revenue (INR Cr) Revenue Mix Other* 9,031 Injectables 1% Orals Dietary 7% Supplements 69% 7,442 6,827 11% 6,079 Share of Non- 4,832 Orals significantly OTC improved 3% Injectables Orals 16% 93% FY15 FY16 FY17 FY18 FY19 FY14 FY19 Cumulative ANDA Filings and Approvals Filing Mix
Slide 8: US Business – Segment Wise Highlights
US Business – Segment Wise Highlights Orals Injectables • 69% of overall US business in FY19 • 16% of overall US business in FY19 USA • Rx share increased to 7.0% (MAT Mar 2019) from 5.3% • Filed 21 ANDAs and lunched 12 products in FY19 (MAT Mar 2018)* • Future pipeline includes • Filed 36 ANDAs and
Slide 9: US: Expanding Portfolio Mix Towards Differentiated Products
US: Expanding Portfolio Mix Towards Differentiated Products Portfolio mix is complemented with the introduction of high-value products ANDAs Addressable Market in US$ Bn 16.8 24.8 24.7 167 5.7* 95 84 3.6 0.8 9.2 8.0 1.4 0.7 42 0.5 0.4 1.3 32 24 30 19 17 12 14 2 3 Anti Diabetic ARV CNS Controlled CVS
Slide 10: Sandoz’s Dermatology and Oral Solids Businesses – Acquisition overview
Sandoz’s Dermatology and Oral Solids Businesses – Acquisition* overview Aurobindo Pharma USA Inc. entered into a definitive agreement with Sandoz Inc., USA to acquire its dermatology and oral solids businesses Acquired portfolio with c.70% revenue contribution by oral solids and c.30% by dermato
Slide 11: Post-Acquisition: 2nd Largest Generic Player in the US
Aurobindo would become the 2nd Largest Generic Player in the US Post Sandoz’s businesses acquisition Market Share in the US by Number of Prescriptions Dispensed 2nd 4th 14.3% 8.6% 3.1% 6.4% 5.7% 5.5% 4.1% 3.3% 3.0% 3.0% 2.8% 2.8% 2.7% 5.5% 3.1% 1.0% Post-Acquisition 10 1) Source: IQVIA MAT Jul 2018
Slide 12: Acquisition of branded oncology injectables from Spectrum Pharmaceuticals
Acquisition of branded oncology injectables from Spectrum Pharmaceuticals - Overview Acrotech Biopharma, a step-down subsidiary of Aurobindo Pharma Limited has acquired portfolio of seven marketed oncology injectable products from Spectrum Pharmaceuticals Acquisition brings-in an experienced bra
Slide 13: EU Business Highlights
EU Business Highlights Strong foothold in Europe Revenue (INR Cr) • Operations in 11 countries with full fledged Pharmacy, Hospital 12% CAGR in FY15 – FY19 4,960 4,354 and Tender sales infrastructure with commercialized 450+ INNs • Ranks amongst the Top 10@ Generic companies in four out of 3,195 3
Slide 14: Aurobindo’s Footprint in Europe Post Apotex Acquisition
Aurobindo’s Footprint in Europe Post Apotex Acquisition France Spain: Existing + Acquired ► Ranks #1 by volume for hospital segment; 5th ► 13th largest generic company position in the retail market ► Number of products total marketed: 182 ► Number of products currently marketed: 268 Germany Netherla
Slide 15: Growth Markets & ARV Business – Highlights
Growth Markets & ARV Business – Highlights Growth Markets Business Revenue (INR Cr) 20% CAGR in FY15-FY19 1,194 Key markets includes Canada, Brazil and South Africa 897 Targeted to build branded generics presence in select markets 756 646 569 In the process of strengthening operations and port
Slide 16: API Business - Highlights
API Business - Highlights API capacity is strategic in-terms of vertical integration and supply reliability Revenue (INR Cr) Additional investments are made for capacity creation and capability building 3,403 3,042 2,962 2,884 2,706 Customers include innovator and large generic companies API
Slide 17: Consolidated Financial Performance
Consolidated Financial Performance Q4 Q4 % Q3 % Value INR Cr FY19 FY18 Chg FY19 Chg Formulations 4,373.6 3,248.6 34.6 4,347.8 0.6 API 916.8 799.6 14.6 921.7 -0.5 Formulations % of sales 82.7% 80.2% 82.5% Revenue from Operations 5,292.2 4,049.1 30.7 5,269.7 0.4 Gross Profit 2,919.6 2,379.6 22.7 2,879
Slide 18: Financial Performance
Financial Performance Revenue from Operations (INR Cr) EBITDA & PAT Margin (%) EPS (INR/Share) 23.0 39.3 41.4 19,564 22.8 22.8 40.4 16,500 21.2 34.7 13,955 15,090 19.9 19.8 19.7 20.2 12,121 18.4 27.0 16.5 15.3 14.7 14.5 13.0 12.1 FY15 FY16 FY17 FY18 FY19 FY15 FY16 FY17 FY18 FY19 EBITDA Margin Adj PB
Slide 19: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-16 Mar-17 Mar-18 Dec-18 Mar-19 Closing Rate1 US$ = 66.25 64.85 65.17 69.775 69.155 INR Fx Loan restated in 4,956.7 3,121.5 4,766.9 5,381.8 6,959.0 748 481 731 771 1,006 INR Rupee Loan 46.9 244.8 4.1 289.7 8.1 Sales Tax Deferment 41.9 0.0 0.0 0.0 0.
Slide 20: Focus on Building a Diverse and Robust Specialty Products Portfolio
Focus on Building a Diverse and Robust Specialty Products Portfolio Oncology & Hormones Peptides Depot Injections Controlled Substances Topicals Transdermal Patches Inhalers Nasals Biosimilars Vaccines 505(b)(2) products Consumer Healthcare 19
Slide 21: Specialty Products Portfolio (1/2)
Focus on Building a Diverse and Robust Specialty Products Portfolio (1/2) Oncology & Topicals Nasals Peptides Depot Injection Hormones Products under 79 22 5 14 4 development Addressable Market Size $45 Bn $5 Bn $0.5 Bn $12.2 Bn $3.6 Bn Filing Status ANDAs*: Oncology- ANDAs*: 3 ANDAs*: 2 6 DMFs file
Slide 22: Specialty Products Portfolio (2/2)
Focus on Building a Diverse and Robust Specialty Products Portfolio (2/2) Transdermal Inhalers Biologics Vaccines Patches Products under 8 9 6* 1 development Addressable Market Size $3.2 Bn $9.5 Bn $35 Bn $6.2 Bn Filing to start from FY20 FY20 FY21 FY21 Filing Target To file all products To file all
Slide 23: Enhanced Research & Development Capabilities
Enhanced Research & Development Capabilities R&D Spend – INR Cr (as % of revenue) 5 R&D centers in Hyderabad, India >1,500 scientists and analysts Focused on difficult to develop APIs, peptides, etc. 5.5%* Develop modern process technologies like enzyme chemistry 5.0%* 872 4.3%* Dosage Form R&
Slide 24: Annexure
Annexure Raleigh, NC 23
Slide 25: Filing details as on 31st Mar 2019
Filing details as on 31st Mar 2019 As at As at As at As at As at As at Category Approvals Mar 14 Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 Formulations US* 336 376 398 429 478 541 403 (FA: 377, TA:26) 2,385 Dossiers (259 Europe** 1,542 1,756 2,224 2,521 2,848 3003 products) 208 Registrations (98 SA** 334 3
Slide 26: Extensive Manufacturing Base with High Quality Control and Compliance
Extensive Manufacturing Base with High Quality Control and Compliance Finished Dose Formulations Active Pharma Ingredients Site Product Capabilities Site Product Capabilities Unit III Non antibiotics, ARVs / Orals Unit I CVS, CNS, Anti-Allergics, Non-Sterile Unit IV Injectables (Non-antibiotics)&Oph
Slide 27: Shareholding Pattern
Shareholding Pattern Group As on As on As on Non-Promoter Holding 48.1% as on 31st Mar 2019 31 Mar 17 31 Mar 18 31 Mar 19 Promoter Group 51.9% 51.9% 51.9% FII 21.0% 18.0% 21.5% Retail, 10.0 MF & Insurance 12.4% 15.6% 13.7% FII, 21.5 Other Other Bodies Corporates 3.6% 2.9% 2.9% Bodies Corp, 2.9 Retai
Slide 28: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-6, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Registered Of